Kellie D. Nance

1.5k citations

21 papers · 760 indexed · 1 hit paper · h-index 13

Co-authors: Jordan L. Meier Craig W. Lindsley Carrie K. Jones P. Jeffrey Conn David Bartee Colleen M. Niswender Hyekyung P. Cho Anna L. Blobaum
Topics: Receptor Mechanisms and Signaling (10 papers)Neuroscience and Neuropharmacology Research (7 papers)RNA modifications and cancer (4 papers)
Cited by: Molecular Biology Cellular and Molecular Neuroscience Cancer Research
Journals: Journal of the American Chemical Society Journal of Medicinal Chemistry Tetrahedron Letters
Partner nations: United States Australia Israel

In The Last Decade

Kellie D. Nance

21 papers receiving 747 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines

2021 283 citations Kellie D. Nance, Jordan L. Meier ACS Central Science profile →

Peers

Countries citing papers authored by Kellie D. Nance

Since Specialization

Citations

This map shows the geographic impact of Kellie D. Nance's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kellie D. Nance with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kellie D. Nance more than expected).

Fields of papers citing papers by Kellie D. Nance

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kellie D. Nance. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kellie D. Nance. The network helps show where Kellie D. Nance may publish in the future.

Co-authorship network of co-authors of Kellie D. Nance

This figure shows the co-authorship network connecting the top 25 collaborators of Kellie D. Nance. A scholar is included among the top collaborators of Kellie D. Nance based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kellie D. Nance. Kellie D. Nance is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Applications of Machine Learning Approaches for the Discovery of SARS-CoV-2 PLpro Inhibitors 2025 ·Journal of Chemical Information and Modeling ·(unknown),Kellie D. Nance,Dirgha Raj Joshi,Stephen C. Kales,Lin Ye,Xin Hu,Khalida Shamim,Alexey Zakharov	2
2	Site-Specific Synthesis of N ⁴ -Acetylcytidine in RNA Reveals Physiological Duplex Stabilization 2022 ·Journal of the American Chemical Society ·David Bartee,Kellie D. Nance,Jordan L. Meier	42
3	Conditional Covalent Lethality Driven by Oncometabolite Accumulation 2022 ·ACS Chemical Biology ·(unknown),Kellie D. Nance,Daniel W. Bak,Supuni Thalalla Gamage,(unknown),(unknown),W. Marston Linehan,Eranthie Weerapana,Jordan L. Meier	3
4	Cytidine acetylation yields a hypoinflammatory synthetic messenger RNA 2021 ·Cell chemical biology ·Kellie D. Nance,Supuni Thalalla Gamage,(unknown),Acong Yang,Michaella J. Levy,(unknown),Laurence Florens,Michael P. Washburn,Shuo Gu,Joost J. Oppenheim,Jordan L. Meier	23
5	Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccinesbreakdown → 2021 ·ACS Central Science ·Kellie D. Nance,Jordan L. Meier	283
6	A Systems Chemoproteomic Analysis of Acyl-CoA/Protein Interaction Networks 2019 ·Cell chemical biology ·Michaella J. Levy,David C. Montgomery,Mihaela E. Sardiu,(unknown),(unknown),Kellie D. Nance,Abigail L. Thorpe,Stephen D. Fox,Qishan Lin,Þorkell Andrésson,Laurence Florens,Michael P. Washburn,Jordan L. Meier	21
7	Total synthesis of natural (−)- and unnatural (+)-Melearoride A 2019 ·Tetrahedron Letters ·(unknown),(unknown),Kellie D. Nance,Craig W. Lindsley	7
8	A Chemical Signature for Cytidine Acetylation in RNA 2018 ·Journal of the American Chemical Society ·Justin M. Thomas,Chloe A. Briney,Kellie D. Nance,(unknown),Abigail L. Thorpe,Stephen D. Fox,Marie‐Line Bortolin‐Cavaillé,Aldema Sas‐Chen,Daniel Arango,Shalini Oberdoerffer,Jérôme Cavaillé,Þorkell Andrésson,Jordan L. Meier	81
9	A Novel M ₁ PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity 2018 ·ACS Chemical Neuroscience ·Jerri M. Rook,(unknown),Hyekyung P. Cho,Pedro M. García-Barrantes,Sean P. Moran,James Maksymetz,Kellie D. Nance,Jonathan W. Dickerson,(unknown),Sichen Chang,Joel M. Harp,Anna L. Blobaum,Colleen M. Niswender,Carrie K. Jones,Shaun R. Stauffer,P. Jeffrey Conn,Craig W. Lindsley	45
10	The discovery of VU0486846: steep SAR from a series of M1 PAMs based on a novel benzomorpholine core 2018 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Hyekyung P. Cho,Pedro M. García-Barrantes,Joseph D. Panarese,James M. Salovich,Kellie D. Nance,Darren W. Engers,Jerri M. Rook,Anna L. Blobaum,Colleen M. Niswender,Shaun R. Stauffer,P. Jeffrey Conn,Craig W. Lindsley	11
11	Continued optimization of the M5 NAM ML375: Discovery of VU6008667, an M5 NAM with high CNS penetration and a desired short half-life in rat for addiction studies 2017 ·Bioorganic & Medicinal Chemistry Letters ·Kevin McGowan,Kellie D. Nance,(unknown),Thomas M. Bridges,P. Jeffrey Conn,Carrie K. Jones,Craig W. Lindsley	23
12	Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core 2017 ·Journal of Medicinal Chemistry ·Kellie D. Nance,Emily Days,C. David Weaver,(unknown),(unknown),Hyekyung P. Cho,Colleen M. Niswender,Anna L. Blobaum,Kevin D. Niswender,Craig W. Lindsley	8
13	Ligand-based virtual screen for the discovery of novel M5 inhibitor chemotypes 2016 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),(unknown),Kellie D. Nance,Kevin McGowan,P. Jeffrey Conn,Carrie K. Jones,Jens Meiler,Craig W. Lindsley	16
14	Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetration 2016 ·Bioorganic & Medicinal Chemistry Letters ·Joseph D. Panarese,(unknown),(unknown),Kellie D. Nance,Pedro M. García-Barrantes,Sichen Chang,Ryan D. Morrison,Anna L. Blobaum,Colleen M. Niswender,Shaun R. Stauffer,P. Jeffrey Conn,Craig W. Lindsley	9
15	Diverse Effects on M₁ Signaling and Adverse Effect Liability within a Series of M₁ Ago-PAMs 2016 ·ACS Chemical Neuroscience ·Jerri M. Rook,Masahito Abe,Hyekyung P. Cho,Kellie D. Nance,Vincent B. Luscombe,(unknown),Jonathan W. Dickerson,(unknown),Pedro M. García-Barrantes,Darren W. Engers,Julie L. Engers,Sichen Chang,(unknown),Anna L. Blobaum,Colleen M. Niswender,Carrie K. Jones,P. Jeffrey Conn,Craig W. Lindsley	41
16	Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M₁PAM VU6004256 2016 ·ACS Chemical Neuroscience ·Michael Grannan,Catharine A. Mielnik,Sean P. Moran,Robert W. Gould,(unknown),(unknown),Michael Bubser,Amy J. Ramsey,Masahito Abe,Hyekyung P. Cho,Kellie D. Nance,Anna L. Blobaum,Colleen M. Niswender,P. Jeffrey Conn,Craig W. Lindsley,Carrie K. Jones	34
17	A Novel and Selective PAR4 Antagonist: ML354 2015 ·(unknown),Matthew T. Duvernay,M. Schulte,Kellie D. Nance,Bruce J. Melancon,Julie L. Engers,Michael R. Wood,Heidi E. Hamm,Craig W. Lindsley	2
18	Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354 2014 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),(unknown),Matthew T. Duvernay,M. Schulte,Kellie D. Nance,Bruce J. Melancon,Julie L. Engers,Charles W. Locuson,(unknown),J. Scott Daniels,Wenjun Wu,Craig W. Lindsley,Heidi E. Hamm,Shaun R. Stauffer	29
19	Discovery of (S)-2-Cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): A Novel, CNS Penetrant Glucagon-Like Peptide 1 Receptor (GLP-1R) Positive Allosteric Modulator (PAM) 2014 ·Journal of Medicinal Chemistry ·(unknown),Kellie D. Nance,Patrick R. Gentry,Emily Days,C. David Weaver,Colleen M. Niswender,Analisa D. Thompson,Carrie K. Jones,(unknown),Ryan D. Morrison,J. Scott Daniels,Kevin D. Niswender,Craig W. Lindsley	36
20	Design of Fluorine-Containing 3,4-Diarylfuran-2(5H)-ones as Selective COX-1 Inhibitors 2014 ·ACS Medicinal Chemistry Letters ·(unknown),(unknown),Kebreab Ghebreselasie,(unknown),Brenda C. Crews,Kellie D. Nance,(unknown),Lawrence J. Marnett	32

About Kellie D. Nance

Kellie D. Nance is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Computational Theory and Mathematics, having authored 21 papers that have together received 760 indexed citations. Recurring topics across this work include Receptor Mechanisms and Signaling (10 papers), Neuroscience and Neuropharmacology Research (7 papers) and RNA modifications and cancer (4 papers). The work is most often cited by research in Molecular Biology (600 citations), Cellular and Molecular Neuroscience (150 citations) and Cancer Research (84 citations). Kellie D. Nance has collaborated with scholars based in United States, Australia and Israel. Frequent co-authors include Jordan L. Meier, Craig W. Lindsley, Carrie K. Jones, P. Jeffrey Conn, David Bartee, Colleen M. Niswender, Hyekyung P. Cho, Anna L. Blobaum, Þorkell Andrésson and Stephen D. Fox. Their work appears in journals such as Journal of the American Chemical Society, Journal of Medicinal Chemistry and Tetrahedron Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact